World
Merck and Moderna release detailed cancer vaccine data at ESMO A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
Dr. Kai NakamuraChief Science CorrespondentPublished Oct 22, 2026 at 3:29 PM EDT · 1 min read
Merck and Moderna release detailed cancer vaccine data at ESMO A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment. A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.